Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) insider Fouad Namouni sold 3,633 shares of the stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Blueprint Medicines Stock Up 0.6 %
Shares of NASDAQ:BPMC opened at $88.61 on Monday. The company’s fifty day moving average is $92.59 and its two-hundred day moving average is $99.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $121.90. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of -18.42 and a beta of 0.58.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The firm had revenue of $138.20 million for the quarter, compared to analyst estimates of $104.02 million. During the same quarter in the prior year, the business earned ($2.19) earnings per share. Blueprint Medicines’s quarterly revenue was up 139.9% on a year-over-year basis. Equities analysts anticipate that Blueprint Medicines Co. will post -3.99 EPS for the current year.
Institutional Trading of Blueprint Medicines
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on BPMC. Needham & Company LLC restated a “buy” rating and issued a $130.00 price target on shares of Blueprint Medicines in a report on Thursday, August 1st. Robert W. Baird raised their price target on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Oppenheimer lifted their price target on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, July 8th. Guggenheim upped their price objective on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Baird R W upgraded Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $120.00.
Read Our Latest Report on BPMC
About Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Stories
- Five stocks we like better than Blueprint Medicines
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.